Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...

It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 ...

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

Important messages require accurate transmission. Big genes are especially challenging. During processing, introns (non-coding elements) are snipped out and exons (coding segments) pasted together to ...

Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...